Core Laboratories
Core Laboratories' revenue rose 0.5% to $526 million in fiscal 2025. Its operating margin was 10.7%, down from 11.2% a year earlier. Free cash flow was $26 million, down 42.0%. It paid out $14 million in dividends and buybacks, 55% of free cash flow. The diluted share count fell 1.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Core Laboratories does
Core Laboratories sells measurement services and products to oil and gas companies. Its labs study reservoir rock and fluids such as crude oil, natural gas and water, so clients can judge how a field performs and recover more oil and gas. It also helps clients evaluate underground sites for carbon capture and storage. Its clients are mostly major, national and independent oil companies.
It reports two segments. Reservoir Description covers lab analysis of rocks and fluids, field services, studies and the lab equipment it makes. Production Enhancement covers products and services for well completions, perforating, stimulation and well abandonment, including perforating products it makes. Revenue comes from these services and product sales, mainly to the oil and gas industry.
Core Lab was established in 1936. It has over 70 offices in more than 50 countries and approximately 3,300 employees. In 2023 it changed its home from the Netherlands to Delaware through a redomestication.
Its biggest risks, as it describes them
- Falling spending by oil and gas companies in downturns, which lowers demand for its services.
- Conflict in the Middle East, where it owns and runs several laboratories.
- Risks of doing business in many countries, since it relies on its international operations.
- Cost-cutting steps that could disrupt operations or delay new products.
- Holding too much unneeded inventory if it misjudges what clients will order.
Income statement
From fiscal 2021 to 2025, earnings per share grew 10.7% a year and net income 10.8% a year, as new shares raised the share count by 1% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 18 | 15 | 15 | 19 | 23 |
| Debt incl. finance leases | — | 175 | 166 | 128 | 113 |
| Net debt (negative means net cash) | — | 160 | 151 | 109 | 90 |
| Net debt to EBITDA | — | 2.7x | 2.1x | 1.5x | 1.3x |
| Debt to equity | — | 0.9x | 0.7x | 0.5x | 0.4x |
| Interest coverage | 5.0x | 3.6x | 4.1x | 4.7x | 5.3x |
| Current ratio | — | 2.0x | 2.5x | 2.2x | 2.0x |
| Quick ratio | — | 1.5x | 1.7x | 1.6x | 1.5x |
Cash flow
Projections
Project Core Laboratories' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $53,900 of Core Laboratories shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Lawrence BrunoChairman and CEO, Director | Bought | 5,000 | $10.78 | $53,900 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 5 of 9 | 7 of 9 |
| Rule of 40 | 6.9% | 11.2% | 5.4% |
| Altman Z'' | 3.46 | 3.61 | 3.75 |
| Accruals ratio | 2.0% | −4.3% | −1.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 7 of 9 | 5 of 9 | 7 of 9 |
Compare
Put Core Laboratories side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Core Laboratories | FY25 | 0.5% | 10.7% | 4.9% | 10.3% | 1.3x | 7 | |
| Ranger Energy Services | FY25 | −4.2% | 2.8% | 7.8% | 3.8% | 0.1x | 4 | Compare |
| Solaris Energy Infrastructure | FY25 | 98.7% | 21.8% | −70.3% | 14.1% | −0.8x | — | Compare |
| TETRA Technologies | FY25 | 5.3% | 8.8% | 3.1% | 6.8% | 1.3x | 5 | Compare |
| Oil States International | FY25 | −3.4% | −14.6% | 11.1% | −12.4% | — | 5 | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 470 | 490 | 510 | 524 | 526 |
| Revenue growth | — | 4.1% | 4.1% | 2.8% | 0.5% |
| Gross profit | — | 96 | 110 | 103 | 109 |
| Research and development | — | — | — | — | — |
| Operating income | 45 | 42 | 55 | 59 | 56 |
| Net income | 20 | 20 | 37 | 31 | 30 |
| Diluted EPS (US$) | 0.42 | 0.42 | 0.77 | 0.66 | 0.63 |
| Diluted shares (millions) | 47 | 47 | 48 | 48 | 47 |
| Cash flow | |||||
| Cash from operations | 37 | 25 | 25 | 56 | 37 |
| Capital expenditure | 14 | 10 | 11 | 12 | 11 |
| Free cash flow | 23 | 15 | 14 | 44 | 26 |
| Dividends paid | 2 | 2 | 2 | 2 | 2 |
| Share buybacks | 8 | 4 | 2 | 5 | 12 |
| Acquisitions | 0 | 0 | 0 | 0 | 1 |
| Stock-based compensation | 19 | 8 | 14 | 4 | 7 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 18 | 15 | 15 | 19 | 23 |
| Debt incl. finance leases | — | 175 | 166 | 128 | 113 |
| Total assets | 581 | 578 | 586 | 585 | 584 |
| Total liabilities | — | 395 | 362 | 333 | 312 |
| Shareholders' equity | 161 | 184 | 225 | 247 | 266 |
| Margins and ratios | |||||
| Gross margin | — | 19.6% | 21.5% | 19.7% | 20.7% |
| Operating margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% |
| Net margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| Free cash flow margin | 4.9% | 3.0% | 2.8% | 8.5% | 4.9% |
| Rule of 40 (growth + FCF margin) | — | 7.2% | 6.9% | 11.2% | 5.4% |
| Return on capital | — | — | 13.7% | 11.1% | 10.3% |
| Return on equity | — | 11.3% | 17.9% | 13.3% | 11.6% |
| Return on assets | — | 3.4% | 6.3% | 5.4% | 5.1% |
| Net debt to EBITDA | — | 2.7x | 2.1x | 1.5x | 1.3x |